Difference between revisions of "Waldenström macroglobulinemia - historical"
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 50%; text-align:center;"" to "{| class="wikitable" style="width: 40%; text-align:center;"") Tags: mobile edit mobile web edit |
Warner-admin (talk | contribs) m (Text replacement - "|Phase II" to "|Phase 2") |
||
| Line 22: | Line 22: | ||
|- | |- | ||
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext Furman et al. 2016 (GSK 110921)] | |[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext Furman et al. 2016 (GSK 110921)] | ||
| − | |style="background-color:#91cf61"|Phase | + | |style="background-color:#91cf61"|Phase 2 |
|- | |- | ||
|} | |} | ||
| Line 37: | Line 37: | ||
|- | |- | ||
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext Furman et al. 2016 (GSK 110921)] | |[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext Furman et al. 2016 (GSK 110921)] | ||
| − | |style="background-color:#91cf61"|Phase | + | |style="background-color:#91cf61"|Phase 2 |
|- | |- | ||
|} | |} | ||
| Line 62: | Line 62: | ||
|- | |- | ||
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext Furman et al. 2016 (GSK 110921)] | |[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext Furman et al. 2016 (GSK 110921)] | ||
| − | |style="background-color:#91cf61"|Phase | + | |style="background-color:#91cf61"|Phase 2 |
|- | |- | ||
|} | |} | ||
| Line 77: | Line 77: | ||
|- | |- | ||
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext Furman et al. 2016 (GSK 110921)] | |[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext Furman et al. 2016 (GSK 110921)] | ||
| − | |style="background-color:#91cf61"|Phase | + | |style="background-color:#91cf61"|Phase 2 |
|- | |- | ||
|} | |} | ||
Revision as of 17:42, 12 February 2022
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? Please go to the main WM regimen page to find other regimens.
3 regimens on this page
5 variants on this page
|
First-line therapy
Ofatumumab monotherapy
| back to top |
Regimen variant #1
| Study | Evidence |
|---|---|
| Furman et al. 2016 (GSK 110921) | Phase 2 |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 1000 mg IV once per day on days 8, 15, 22
4-week course
Regimen variant #2
| Study | Evidence |
|---|---|
| Furman et al. 2016 (GSK 110921) | Phase 2 |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 2000 mg IV once per day on days 8, 15, 22, 29
5-week course
References
- GSK 110921: Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. link to original article contains protocol link to PMC article PubMed NCT00811733
Relapsed or refractory
Ofatumumab monotherapy
| back to top |
Regimen variant #1
| Study | Evidence |
|---|---|
| Furman et al. 2016 (GSK 110921) | Phase 2 |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 1000 mg IV once per day on days 8, 15, 22
4-week course
Regimen variant #2
| Study | Evidence |
|---|---|
| Furman et al. 2016 (GSK 110921) | Phase 2 |
Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.
Targeted therapy
- Ofatumumab (Arzerra) 300 mg IV once on day 1, then 2000 mg IV once per day on days 8, 15, 22, 29
5-week course
References
- GSK 110921: Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. link to original article contains protocol link to PMC article PubMed NCT00811733